The chief of staff of Hungary's Prime Minster, Gergely Gulyas, said on 14 January 2021 that Hungary has reached a deal with China National Pharmaceutical Group Corp ( Sinopharm) to buy COVID-19 vaccines developed by the company, Reuters news agency reported on Thursday.
According to Gulyas, vaccine shipments under the European Union's programme were arriving to Hungary way too slow.
Gulyas was also quoted as telling a government briefing that the second wave of the COVID-19 pandemic has peaked in Hungary and new infections have dropped but restrictions cannot be eased yet.
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV